Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 3 |
List of Tables | 4 | 1 |
List of Figures | 4 | 1 |
Introduction | 5 | 1 |
Global Markets Direct Report Coverage | 5 | 1 |
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Overview | 6 | 1 |
Therapeutics Development | 7 | 4 |
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Products under Development by Stage of Development | 7 | 1 |
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Products under Development by Therapy Area | 8 | 1 |
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Products under Development by Indication | 9 | 2 |
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Pipeline Products Glance | 11 | 2 |
Late Stage Products | 11 | 1 |
Early Stage Products | 12 | 1 |
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Products under Development by Companies | 13 | 4 |
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Therapeutics Assessment | 17 | 5 |
Assessment by Monotherapy/Combination Products | 17 | 1 |
Assessment by Mechanism of Action | 18 | 1 |
Assessment by Route of Administration | 19 | 2 |
Assessment by Molecule Type | 21 | 1 |
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Companies Involved in Therapeutics Development | 22 | 3 |
Karyopharm Therapeutics, Inc. | 22 | 2 |
Stemline Therapeutics, Inc. | 24 | 1 |
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Drug Profiles | 25 | 26 |
KPT-251 Drug Profile | 25 | 1 |
KPT-276 Drug Profile | 26 | 1 |
KPT-350 Drug Profile | 27 | 2 |
KPT-8602 Drug Profile | 29 | 2 |
selinexor Drug Profile | 31 | 17 |
SL-801 Drug Profile | 48 | 2 |
verdinexor Drug Profile | 50 | 1 |
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Dormant Projects | 51 | 3 |
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Discontinued Products | 54 | 1 |
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Featured News &Press Releases | 55 | 15 |
Jul 27, 2016: Karyopharm to Present Updated Phase 2 Clinical Data from SIGN Study at European Society of Medical Oncology 2016 Annual Meeting | 55 | 1 |
Jul 27, 2016: Karyopharms Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology | 56 | 1 |
Jun 16, 2016: Karyopharm Outlines Key Selinexor Clinical Development Achievements | 57 | 1 |
Jun 10, 2016: Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data at 2016 European Hematology Association Annual Meeting | 58 | 1 |
Jun 10, 2016: Karyopharm Therapeutics Presents data on KPT-8602 at 2016 European Hematology Association Annual Meeting | 59 | 1 |
Jun 06, 2016: Moffitt researchers present phase 1 study results of selinexor combination therapy; multiple myeloma | 60 | 1 |
May 19, 2016: Karyopharm to Present Preliminary STOMP Phase 1B Clinical Data at 2016 European Hematology Association Annual Meeting | 60 | 1 |
May 18, 2016: Karyopharm to Present Selinexor Clinical Data at the American Society of Clinical Oncology Annual Meeting | 61 | 2 |
May 03, 2016: Stemline Therapeutics Clears First Cohort of Patients in Ongoing SL-801 Phase 1 Trial | 63 | 1 |
Apr 20, 2016: Karyopharm Presents Data Demonstrating the Potential of Nuclear Export Protein Exportin 1 (XPO1) Inhibition in the Treatment of Traumatic Brain Injury | 63 | 1 |
Mar 31, 2016: Karyopharm Receives NIAID Grant to Advance Development of KPT-350 for the Treatment of Lupus | 64 | 1 |
Mar 16, 2016: Karyopharm to Present Data on Oncology drug Selinexor (KPT-330) at the 2016 American Association for Cancer Research Annual Meeting | 65 | 2 |
Mar 16, 2016: Karyopharm to Present Data on Oncology drug KPT-8602 at the 2016 American Association for Cancer Research Annual Meeting | 67 | 1 |
Mar 04, 2016: Karyopharm s Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology | 68 | 1 |
Jan 19, 2016: Karyopharm Initiates Second Generation SINE Compound Clinical Trial in Multiple Myeloma | 69 | 1 |
Appendix | 70 | 2 |
Methodology | 70 | 1 |
Coverage | 70 | 1 |
Secondary Research | 70 | 1 |
Primary Research | 70 | 1 |
Expert Panel Validation | 70 | 1 |
Contact Us | 70 | 1 |
Disclaimer | 71 | 1 |